Core Viewpoint - The stock of Shandong Boyuan Pharmaceutical Chemical Co., Ltd. has experienced significant fluctuations, with a year-to-date increase of 151.82% but a recent decline of 3.42% over the last five trading days [1] Group 1: Company Overview - Shandong Boyuan Pharmaceutical Chemical Co., Ltd. was established on August 6, 2008, and is located in Shouguang City, Shandong Province [2] - The company specializes in the research, production, and sales of fine chemicals, including organic iodides, inorganic iodides, precious metal catalysts, luminescent materials, and hexamethyldisilazane [2] - The main revenue composition includes iodides (74.56%), specialty functional chemicals (12.79%), trading business (9.94%), and others (2.72%) [2] Group 2: Financial Performance - For the period from January to September 2025, Boyuan achieved operating revenue of 1.073 billion yuan, representing a year-on-year growth of 6.60% [2] - The net profit attributable to the parent company was 132 million yuan, showing a year-on-year decrease of 22.53% [2] - Cumulative cash dividends since the A-share listing amount to 88.408 million yuan [3] Group 3: Shareholder and Market Activity - As of October 20, 2025, the number of shareholders increased by 25.58% to 13,300, with an average of 2,502 circulating shares per person, a decrease of 20.37% [2] - The stock has appeared on the "Dragon and Tiger List" six times this year, with the most recent appearance on October 17, where it recorded a net buy of -20.2738 million yuan [1] - Major shareholders include various new institutional investors, with significant holdings from funds such as Zhonghang New Start Flexible Allocation Mixed A and Hong Kong Central Clearing Limited [3]

Core Insights - On October 24, Boyuan Co., Ltd. saw a stock price increase of 14.34% with a trading volume of 902 million yuan [1] - The company experienced a net financing outflow of 982.88 million yuan on the same day, with a total financing and securities balance of 1.92 billion yuan [1][2] Financing and Trading Data - On October 24, Boyuan Co., Ltd. had a financing purchase of 8970.56 million yuan, with a current financing balance of 1.92 billion yuan, representing 5.58% of the circulating market value [2] - There were no short sales or repayments on the same day, with a short balance of 0.00 yuan [2] Company Overview - Boyuan Co., Ltd. is located in Shouguang City, Shandong Province, and was established on August 6, 2008, with a listing date of December 11, 2024 [2] - The company specializes in the research, production, and sales of fine chemicals, including organic iodides, inorganic iodides, precious metal catalysts, luminescent materials, and hexamethyldisilazane [2] - The main revenue composition includes iodides (74.56%), specialty functional chemicals (12.79%), trading business (9.94%), and others (2.72%) [2] Shareholder and Financial Performance - As of October 20, the number of shareholders for Boyuan Co., Ltd. was 13,300, an increase of 25.58% from the previous period, with an average of 2502 circulating shares per person, a decrease of 20.37% [3] - For the period from January to September 2025, the company reported a revenue of 1.073 billion yuan, a year-on-year increase of 6.60%, while the net profit attributable to shareholders decreased by 22.53% to 132 million yuan [3] Dividend and Institutional Holdings - Boyuan Co., Ltd. has distributed a total of 88.408 million yuan in dividends since its A-share listing [4] - As of September 30, 2025, several new institutional shareholders have emerged among the top ten circulating shareholders, including Zhonghang New Start Flexible Allocation Mixed A and Hong Kong Central Clearing Limited [4]

Core Insights - The chemical products sector experienced a slight increase of 0.11% on October 24, with Boyuan Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3950.31, up 0.71%, while the Shenzhen Component Index closed at 13289.18, up 2.02% [1] Sector Performance - Boyuan Co., Ltd. (301617) closed at 102.79, with a significant increase of 14.34% and a trading volume of 91,000 shares, resulting in a transaction value of 902 million yuan [1] - Yahua Group (002497) saw a rise of 10.03%, closing at 17.88 with a trading volume of 1.2768 million shares [1] - Licheng Industrial (001218) increased by 6.97%, closing at 23.78 with a trading volume of 95,700 shares [1] - Guangdong Hongda (002683) rose by 4.77%, closing at 39.94 with a trading volume of 237,200 shares [1] - Other notable performers include Shengda Biological (603079) up 4.29%, Jianlong Micro-Nano (688357) up 4.04%, and Gaodian New Materials (300200) up 3.86% [1] Capital Flow - The chemical products sector saw a net outflow of 291 million yuan from main funds, while retail investors contributed a net inflow of 379 million yuan [1]

Core Viewpoint - The company reported a revenue of 327 million yuan in Q3 2025, reflecting a year-on-year growth of 4.84%, while net profit decreased by 31.08% to 33.42 million yuan [1] Financial Performance - Q3 2025 revenue reached 327 million yuan, marking a 4.84% increase compared to the same period last year [1] - Net profit for Q3 2025 was 33.42 million yuan, which represents a decline of 31.08% year-on-year [1]

Core Viewpoint - Boyuan Co., Ltd. reported a year-on-year increase in revenue for Q3 2025, but experienced a significant decline in net profit [1] Financial Performance - The company's operating revenue for Q3 2025 was 327 million yuan, representing a year-on-year increase of 4.84% [1] - The net profit attributable to shareholders of the listed company was 33.42 million yuan, showing a year-on-year decrease of 31.08% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 30.78 million yuan, reflecting a year-on-year decline of 31.98% [1]

Core Viewpoint - The company announced the adjustment of the Audit Committee members during the second board meeting scheduled for October 23, 2025 [2] Group 1 - The company, Boyuan Co., has convened its second board meeting to discuss the adjustment of the Audit Committee [2]

Group 1 - The core point of the article is that Boyuan Co., Ltd. held its 11th meeting of the second board of directors on October 23, 2025, to discuss the adjustment of the audit committee members [1] - For the year 2024, Boyuan Co., Ltd. reported that its revenue composition is entirely from the chemical industry, with a 100.0% share [1] - As of the time of reporting, Boyuan Co., Ltd. has a market capitalization of 12 billion yuan [1] Group 2 - The article highlights that the Chinese innovative drug sector has generated 80 billion USD in overseas licensing deals this year [1] - It features an interview with Lu Gang, a partner at Chuangdong Investment, discussing the hot secondary market in biomedicine while noting the cooling of fundraising in the primary market [1]

证券代码：301617 证券简称：博苑股份 公告编号：2025-053 山东博苑医药化学股份有限公司 关于使用部分闲置募集资金及自有资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 山东博苑医药化学股份有限公司（以下简称"公司"或"博苑股份"）于 2025 年 10 月 23 日召开第二届董事会第十一次会议，审议通过了《关于使用部 分闲置募集资金及自有资金进行现金管理的议案》，同意公司在不影响募集资金 投资项目（以下简称"募投项目"）建设和公司正常经营的情况下，使用不超过 人民币 2.5 亿元（含本数）的闲置募集资金和不超过人民币 5 亿元（含本数）的 闲置自有资金进行现金管理，使用期限自董事会审议通过之日起 12 个月内有效。 在上述额度和期限范围内，资金可循环滚动使用。现将具体情况公告如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意山东博苑医药化学股份有限公司首次 公开发行股票注册的批复》（证监许可〔2024〕1415 号）同意注册，博苑股份 首次公开发行人民币普通股（A 股）股票 2,570.00 万股，每股面值 1 ...

Core Insights - The company reported a third-quarter revenue of 327 million yuan, representing a year-on-year increase of 4.84% [1] - The net profit for the third quarter was 33.42 million yuan, showing a year-on-year decline of 31.08% [1] - For the first three quarters, the company achieved a revenue of 1.073 billion yuan, which is a year-on-year growth of 6.60% [1] - The net profit for the first three quarters was 132 million yuan, reflecting a year-on-year decrease of 22.41% [1]

中泰证券股份有限公司 关于山东博苑医药化学股份有限公司使用部分闲置募集资 金及自有资金进行现金管理的核查意见 中泰证券股份有限公司（以下简称"保荐人"）作为山东博苑医药化学股份有 限公司（以下简称"博苑股份"或"公司"）首次公开发行股票并在创业板上市的保 荐人，根据《证券发行上市保荐业务管理办法》《上市公司募集资金监管规则》 《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》等有关法律法规和规范性文件的要求， 对博苑股份使用部分闲置募集资金及自有资金进行现金管理的事项进行了核查， 核查情况及核查意见如下： 一、募集资金基本情况 1 经中国证券监督管理委员会《关于同意山东博苑医药化学股份有限公司首次 公开发行股票注册的批复》（证监许可〔2024〕1415 号）同意注册，博苑股份首 次公开发行人民币普通股（A 股）股票 2,570.00 万股，每股面值 1 元，每股发行 价格为人民币 27.76 元。本次发行募集资金总额为 71,343.20 万元，扣除发行费 用 8,526.43 万元（不含税）后，募集资金净额为 62,816.77 万元。 上述募集 ...